CNVVY:OTC-Convatec Group Plc (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 10.70

Change

+0.15 (+1.42)%

Market Cap

USD 5.29B

Volume

289.00

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group Plc was incorporated in 2016 and is headquartered in Reading, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOY EssilorLuxottica Société ano..

+0.52 (+0.63%)

USD72.63B 42.28 32.10
ESLOF EssilorLuxottica Société ano..

+1.00 (+0.60%)

USD69.36B 42.47 29.91
HOCPF HOYA Corporation

-6.00 (-4.81%)

USD46.03B 44.45 0.24
HOCPY HOYA Corporation

-5.03 (-4.06%)

USD45.83B 48.67 0.24
SDMHF Sartorius Stedim Biotech S.A

-16.00 (-3.48%)

USD41.31B 196.67 74.06
CLPBY Coloplast A/S

-0.11 (-0.72%)

USD32.64B 54.66 5.66
CLPBF Coloplast A/S

-0.50 (-0.32%)

USD32.53B 54.74 5.66
TRUMF Terumo Corporation

-0.92 (-2.26%)

USD30.73B 18.25 0.33
TRUMY Terumo Corporation

-0.63 (-1.55%)

USD30.44B 18.05 0.33
RSMDF ResMed Inc

N/A

USD29.10B 40.38 28.50

ETFs Containing CNVVY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.86% 26% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.86% 26% F 19% F
Trailing 12 Months  
Capital Gain 0.94% 15% F 35% F
Dividend Return 0.65% 24% F 9% F
Total Return 1.59% 16% F 34% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -3.57% 12% F 30% F
Dividend Return 0.62% 69% D+ 23% F
Total Return -2.95% 12% F 29% F
Risk Return Profile  
Volatility (Standard Deviation) 26.16% 76% C 64% D
Risk Adjusted Return -11.26% 9% F 30% F
Market Capitalization 5.29B 62% D- 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 219.79 8% F 4% F
Price/Book Ratio 3.60 62% D- 33% F
Price / Cash Flow Ratio 13.16 29% F 15% F
EV/EBITDA 22.45 32% F 17% F
Management Effectiveness  
Return on Equity 1.56% 31% F 50% F
Return on Invested Capital 6.15% 41% F 62% D-
Return on Assets 4.09% 54% F 81% B-
Debt to Equity Ratio 92.59% 11% F 20% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.74 37% F 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector